Skip to main content
PlainMeds

What the label lists and what reports show

Menotropins side effects

Menotropins's FDA label: “The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; …” FAERS holds 2,088 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is ovarian hyperstimulation syndrome (431 reports).

  • No generic listed

Check it at the source: the menotropins FDA label on DailyMed (effective May 31, 2018); the FDA FAERS public dashboard.

What does the patient leaflet say about side effects?

From the patient leaflet: What are possible side effects of MENOPUR?

MENOPUR may cause serious side effects, including: ovaries that are too large. MENOPUR may cause your ovaries to be abnormally large. Symptoms of large ovaries include bloating or pain in your lower stomach (pelvic) area. If your ovaries become too large your healthcare provider may tell you that you should not have intercourse (sex) so you do not rupture an ovarian cyst. ovarian hyperstimulation syndrome (OHSS). Using MENOPUR may cause OHSS. OHSS is a serious medical condition that can happen when your ovaries produce too many eggs (overstimulated). OHSS can cause fluid to suddenly build up in the area of your stomach, chest, heart, and cause blood clots to form. OHSS may also happen after you stop using MENOPUR. […]

Source: FDA drug label, Ferring Pharmaceuticals Inc., effective May 31, 2018 (SPL set 22c8db95-c3db-1770-8086-31356fbabe35), via openFDA; the full label on DailyMed

What does the label list?

From the label: adverse reactions

The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc.

From the label: adverse reactions, continued

The following serious adverse reactions are discussed elsewhere in the labeling: Abnormal Ovarian Enlargement [see Warnings and Precautions (5.1) ] Ovarian Hyperstimulation Syndrome [see Warnings and Precautions (5.2) ] Atelectasis, acute respiratory distress syndrome and exacerbation of asthma [see Warnings and Precautions (5.3) ] Thromboembolic events [see Warnings and Precautions (5.3) ] Ovarian Torsion [see Warnings and Precautions (5.4) ] Multi-fetal Gestation and Birth [see Warnings and Precautions (5.5) ] Congenital Malformations [see Warnings and Precautions (5.6) ] Ectopic Pregnancy [see Warnings and Precautions (5.7) ] Spontaneous Abortion [see Warnings and Precautions (5.8) ] Ovarian Neoplasms [see Warnings and Precautions (5.9) ] The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

Source: FDA drug label, Ferring Pharmaceuticals Inc., effective May 31, 2018 (SPL set 22c8db95-c3db-1770-8086-31356fbabe35), via openFDA; the full label on DailyMed

What do FAERS reports show?

2,088 reports list menotropins among the medicines taken, each a report of something that happened, not proof the medicine caused it; 32 are coded as a death and 590 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 11 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Ovarian Hyperstimulation Syndrome (named in the label)431
  • Abdominal Distension (named in the label)182
  • Drug Ineffective (a use or a product term, not a reaction)170
  • Injection Site Pain (named in the label)139
  • Headache (named in the label)124
  • Nausea (named in the label)123
  • Abdominal Pain (named in the label)115
  • Ascites94
  • Dyspnoea (named in the label)84
  • Inappropriate Schedule Of Drug Administration (a use or a product term, not a reaction)81
  • Abortion Spontaneous67
  • Fatigue (named in the label)60
  • Vomiting (named in the label)54
  • Dizziness (named in the label)46
  • Maternal Exposure During Pregnancy (a use or a product term, not a reaction)46
  • Drug Exposure During Pregnancy (a use or a product term, not a reaction)45
  • Chest Discomfort44
  • Rash (named in the label)40
  • Maternal Exposure Before Pregnancy (a use or a product term, not a reaction)39
  • Pruritus36
  • Injection Site Erythema33
  • Injection Site Bruising32
  • Pleural Effusion32
  • Pain31
  • Asthenia29

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Menotropins: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions